Annovis Bio (ANVS) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Annovis Bio (ANVS) over the past year, gaining 18.3% versus a loss of 81.2%. Over five years, RNXT leads with a -85.3% price change compared with -97.2% for ANVS. RenovoRx is the larger company by market cap ($45.5 million vs $44.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | RNXT |
|---|---|---|
| Share price | $0.7113 | $0.942 |
| Market cap | $44.12M | $45.45M |
| 1-day change | -4.96% | -10.29% |
| YTD return | -79.44% | +12.14% |
| 1-year return | -81.23% | +18.34% |
| 5-year return | -97.24% | -85.26% |
| EPS (TTM) | $-1.55 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $1.12M |
| Revenue growth (YoY) | — | +2511.63% |
| Net income (latest FY) | $-28.85M | $-11.17M |
| Gross margin | — | 70.88% |
| Operating margin | — | -1113.98% |
| Net margin | — | -994.48% |
| 52-week high | $5.50 | $2.59 |
| 52-week low | $0.62 | $0.77 |
| Distance from 52-week high | -87.07% | -63.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +1376.17% | +656.90% |
| Average volume | 1.82M | 815.75K |
| Shares outstanding | 62.02M | 48.25M |
| Employees | 7 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed ANVS by 99.6 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ANVS vs RNXT FAQ
Which is bigger, Annovis Bio or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $44.12M for Annovis Bio (ANVS).
Which stock has performed better over the past year, ANVS or RNXT?
RNXT returned +18.34% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.